Stability of plasma human immunodeficiency virus load in VACUTAINER PPT plasma preparation tubes during overnight shipment

Journal of Clinical Microbiology

Volumn 38, Issue 1, 2000, Pages 323-326

  Holodniy, Mark ^a,b   Rainen, Lynne ^c   Herman, Steve ^d   Yen Lieberman, Belinda ^e  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY   (United States)

^c BD Technologies   (United States)

^d ROCHE MOLECULAR SYSTEMS   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDETIC ACID;

ARTICLE; CULTURE AND TRANSPORT MEDIA; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PHLEBOTOMY; PLASMA; PRIORITY JOURNAL; SAMPLE; STORAGE; TEMPERATURE; TRANSPORT MEDIUM; TUBE; VIRUS CULTURE; VIRUS LOAD;

ANTICOAGULANTS; BLOOD; EDETIC ACID; HIV SEROPOSITIVITY; HUMANS; REGRESSION ANALYSIS; RNA STABILITY; SPECIMEN HANDLING; TIME FACTORS; TRANSPORTATION; VIRAL LOAD;

EID: 0033986752     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Bland, J. M., and D. G. Altman. 1995. Comparing methods of measurement: why plotting against standard method is misleading. Lancet 346:1085-1087.
2. Centers for Disease Control and Prevention. 1998. Guidelines for the use of antiretroviral therapy in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Morbid. Mortal. Weekly Rep. 47:45-47. (Erratum, 47:619.)
3. Centers for Disease Control and Prevention. 1998. Report of the NIH Panel to Define Principles of Therapy of HIV Infection. Morbid. Mortal. Weekly Rep. 47:1-41.
4. Dickover, R., S. A. Herman, K. Saddiq, D. Wafer, M. Dillon, and Y. J. Bryson. 1998. Optimization of specimen-handling procedures for accurate quantitation of levels of human immunodeficiency virus RNA in plasma by reverse transcriptase PCR. J. Clin. Microbiol. 36:1070-1073.
5. Harrigan, R. 1995. Measuring viral load in the clinical setting. J. Acquir. Immune Defic. Syndr. 10(Suppl. 1):S34-S40.
6. Holodniy, M., D. A. Katzenstein, D. M. Israelski, and T. C. Merigan. 1991. Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction. J. Clin. Investig. 88:1755-1759.
7. Holodniy, M., L. Mole, B. Yen-Lieberman, D. Margolis, C. Starkey, R. Carrol, T. Spahlinger, J. Todd, and J. Brooks Jackson. 1995. Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J. Clin. Microbiol. 33:1562-1565.
8. Holodniy, M., L. Mole, M. Winters, and T. C. Merigan. 1994. Diurnal and short-term stability of HIV virus load as measured by gene amplification. J. Acquir. Immune Defic. Syndr. 7:363-368.
9. Katzenstein, D. A., S. M. Hammer, M. D. Hughes, H. Gundacker, J. B. Jackson, S. Fiscus, S. Rasheed, T. Elbeik, R. Reichman, A. Japour, T. C. Merigan, and M. S. Hirsch. 1996. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team [see comments]. N. Engl. J. Med. 335:1091-1098. (Erratum, 337:1097, 1997.)
10. Katzenstein, T. L., C. Pederson, C. Nielson, J. D. Lundgren, P. H. Jakobsen, and J. Gerstoft. 1996. Longitudinal serum HIV RNA quantification: correlation to viral phenotype at seroconversion and clinical outcome. AIDS 10:167-173.
11. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1966. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170.
12. + lymphocytes as prognostic markers of HIV-1 infection [see comments]. Ann. Intern. Med. 126:946-954.
13. Mellors, J. W., C. R. Rinaldo, Jr., P. Gupta, R. M. White, J. A. Todd, and L. A. Kingsley. 1996. Prognosis in HIV-1 infections predicted by the quantity of virus in plasma [see comments]. Science 272:1167-1170. (Erratum, 275: 14.)
14. + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS [see comments]. N. Engl. J. Med. 334:426-431.
15. + lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure. Veterans Affairs Cooperative Study Group on AIDS [see comments]. Ann. Intern. Med. 126:939-945.
16. Revets, H., D. Marissens, S. De Wit, P. Lacor, N. Clumeck, S. Lauwers, and G. Zissis. 1996. Comparative evaluation of NASBA HIV-1 RNA QT, AMPLICOR-HIV Monitor, and QUANTIPLEX HIV RNA assay, three methods for quantification of human immunodeficiency virus type 1 RNA in plasma. J. Clin. Microbiol. 34:1058-1064.
17. Semple, M., C. Loveday, I. Weller, and R. Tedder. 1991. Direct measurement of viraemia in patients infected with HIV-1 and its relationship to disease progression and zidovudine therapy. J. Med. Virol. 35:38-45.
18. Winters, M. A., L. B. Tan, D. A. Katzenstein, and T. C. Merigan. 1993. Biological variation and quality control of plasma human immunodeficiency virus type 1 RNA quantitation by reverse transcriptase polymerase chain reaction. J. Clin. Microbiol. 31:2960-2966.